SYRE
Spyre Therapeutics, Inc.Company with tickers: SYRE
CIK
1636282
CUSIP
00773J202
Shares Outstanding
86,841,253
Website
https://www.spyre.com
13F Activity (30d)
48 filings
48 filers
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Peter Harwin | the Board | Resigned | 2026-05-29 |